Crispr Therapeutics AG vs Gemini Space Station Inc — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while Gemini Space Station Inc trades at $4.02 (market cap $512.05M). The key difference: Crispr Therapeutics AG is far larger — about 10.2× Gemini Space Station Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | GEMI | |
|---|---|---|
Market Cap | $5.23B | $512.05M |
Sector | Health | Technology |
52-Week High | $76.78 | $32.52 |
52-Week Low | $44.34 | $3.90 |
Enterprise Value | $3.65B | $502.04M |
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →